COMPANY PROFILE

Boreal Genomics

Explore full profile

Boreal Genomics - circulating tumor DNA analysis

Los Altos, United StatesFounded 2007Biotech & Life Sciences

Valuation $100–250M Last recorded · 2013

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Boreal Genomics

Boreal Genomics specializes in developing advanced linked molecule chemistries designed for high accuracy sequencing and targeted ligation of unknown gene fusions. Operating in the biotechnology sector, Boreal Genomics serves research laboratories and clinical diagnostic centers that require precise genomic analysis. The company’s core product, Linked Target Capture, combines the best of hybridization capture and multiplexed PCR into a streamlined, single-day workflow. This technology is particularly effective for analyzing cell-free DNA, FFPE samples, and genomic DNA. Boreal Genomics generates revenue through the sale of its linked molecule chemistries and associated services, including an Early Access Program that allows labs to trial their innovative panels. The company’s business model focuses on providing cutting-edge genomic solutions that enhance the accuracy and efficiency of genetic research and diagnostics.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2007
Headquarters: Los Altos, United States
Employees: 2
Open positions: None listed
Dealroom signal: 56.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Analytics, Biotechnology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SECONDARYOther financing	Mar 2019	$0	—	Undisclosed	—
SERIES C✓Equity / VC	Oct 2013	$18M	$72M	ARCH Venture Partners · Kearny Venture Partners	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Boreal Genomics website traffic

Latest recorded traffic for Boreal Genomics is 140 monthly website visits, down 48.1% over the last three months. Boreal Genomics's team grew 0% over the past year.

Latest monthly visits140 3-month web change-48.1% 1-year team growth0%

Monthly website visitsMay 2017–May 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DGDeep GenomicsDeep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies	Toronto, Canada	Operational	112	$237M	$720M
GEGeospizaSoftware developer of Next Gen Sequencing DNA Genetic Analysis and LIMS	Seattle, United States	Acquired
INInivataClinical cancer genomics company harnessing the emerging potential of circulating DNA analysis	Morrisville, United States	Acquired
CGCofactor GenomicsCofactor Genomics uses RNA to diagnose disease	San Francisco, United States	Operational
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
LULucencePrecision oncology company dedicated to creating state-of-the-art, highly sensitive liquid biopsy tests for early disease detection and personalized treatment selection	Palo Alto, United States	Operational
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational
IEID-GENE ecodiagnosticsProvides fast, sensitive, and reliable genetic tests for environmental bioassessment and biomonitoring	Geneva, Switzerland	Operational